Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock

Company Overview - Bio-Techne Corp. (TECH) has entered into a distribution agreement with the U.S. Pharmacopeia (USP) to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards alongside its analytical solutions, including the Maurice system, to support global monoclonal antibody and gene therapy development [1][8] - The company has a market capitalization of $8.13 billion and an earnings yield of 3.6%, which is significantly better than the industry's -28.4% yield [4] Recent Developments - The partnership with USP is seen as a significant milestone in advancing Bio-Techne's efforts to provide innovative tools and solutions to the scientific community [2] - Bio-Techne's tools enable efficient and integrated analysis of complex biologics from development to product release, addressing analytical challenges in mAb and gene therapy development [8][6] Market Context - The global monoclonal antibody therapeutics market was valued at $222.6 billion in 2023 and is expected to grow at a compound annual growth rate of 14.5% through 2029, driven by advancements in biotechnology and genetic engineering [10] - The need for consistent mAb quality is increasing as patent protections expire and biosimilar versions become available, necessitating thorough testing of critical quality attributes throughout the development and manufacturing processes [5] Stock Performance - Following the announcement of the partnership, Bio-Techne shares dipped 0.1%, closing at $51.84, but the collaboration is expected to positively influence market sentiment towards TECH stock [3] - Over the past three months, TECH shares have declined 11.6%, while the industry has seen a smaller decline of 2.7% [12]